Alentis Therapeutics Overview
- Year Founded
-
2019
- Status
-
Private
- Employees
-
66
- Latest Deal Type
-
Series D
- Latest Deal Amount
-
$181M
- Investors
-
21
Alentis Therapeutics General Information
Description
Operator of a clinical-stage biopharmaceutical company intended to offer various treatments for cancer and fibrotic diseases. The company develops innovative therapies for the treatment of cancer and other serious diseases, targeting immune checkpoints and modulating the immune system to enhance its ability to fight tumors, enabling medical researchers to treat liver fibrosis, cirrhosis, and liver cancer in patients.
Contact Information
Website
www.alentis.chCorporate Office
- Swiss Innovation Park
- Hegenheimermattweg 167A
- 4123 Allschwil
- Switzerland
Corporate Office
- Swiss Innovation Park
- Hegenheimermattweg 167A
- 4123 Allschwil
- Switzerland
Alentis Therapeutics Timeline
Alentis Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 9. Later Stage VC (Series D) | 11-Nov-2024 | $181M | Completed | Clinical Trials - Phase 2 | ||
| 8. Grant | 09-May-2023 | Completed | Clinical Trials - Phase 2 | |||
| 7. Later Stage VC (Series C) | 13-Apr-2023 | Completed | Clinical Trials - Phase 2 | |||
| 6. Accelerator/Incubator | 26-Jul-2022 | Completed | Clinical Trials - Phase 1 | |||
| 5. Later Stage VC (Series C) | Cancelled | Clinical Trials - Phase 1 | ||||
| 4. Early Stage VC (Series B) | 15-Jun-2021 | Completed | Clinical Trials - Phase 1 | |||
| 3. Early Stage VC (Series A) | 29-Apr-2019 | Completed | Clinical Trials - Phase 1 | |||
| 2. Accelerator/Incubator | 01-Jan-2019 | Completed | Pre-Clinical Trials | |||
| 1. Accelerator/Incubator | 01-Jan-2019 | Completed | Pre-Clinical Trials |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Alentis Therapeutics Comparisons
Industry
Financing
Details
Alentis Therapeutics Competitors (47)
One of Alentis Therapeutics’s 47 competitors is NorthSea Therapeutics, a Venture Capital-Backed company based in Amsterdam, Netherlands.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| NorthSea Therapeutics | Venture Capital-Backed | Amsterdam, Netherlands | ||||
| Onward Therapeutics | Venture Capital-Backed | Taipei, Taiwan | ||||
| Galectin Therapeutics | Corporation | Norcross, GA | ||||
| Sangamo Therapeutics | Formerly VC-backed | Richmond, CA | ||||
| Verastem | Formerly VC-backed | Needham, MA |
Alentis Therapeutics Patents
Alentis Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026057702-A1 | Claudin-1/egfr bispecific antibodies | Pending | 12-Sep-2024 | ||
| WO-2026057723-A1 | Claudin-1/egfr bispecific antibodies for targeted degradation | Pending | 12-Sep-2024 | ||
| AU-2025260873-A1 | Anti-cldn1 antibody-drug conjugates comprising exatecan and methods of use thereof | Pending | 26-Apr-2024 | ||
| WO-2025224337-A1 | Anti-cldn1 antibody-drug conjugates comprising exatecan and methods of use thereof | Pending | 26-Apr-2024 | ||
| AU-2025263283-A1 | Anti-cldn1 antibody-drug conjugates comprising mmae and methods of use thereof | Pending | 26-Apr-2024 | A61K47/68031 |
Alentis Therapeutics Signals
Alentis Therapeutics Investors (21)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Avego Management | PE/Buyout | Minority | ||
| Catalio Capital Management | Venture Capital | Minority | ||
| Double Bioventures | Venture Capital | Minority | ||
| Frazier Healthcare Partners | PE/Buyout | Minority | ||
| Longitude Capital | Venture Capital | Minority |
Alentis Therapeutics FAQs
-
When was Alentis Therapeutics founded?
Alentis Therapeutics was founded in 2019.
-
Where is Alentis Therapeutics headquartered?
Alentis Therapeutics is headquartered in Allschwil, Switzerland.
-
What is the size of Alentis Therapeutics?
Alentis Therapeutics has 66 total employees.
-
What industry is Alentis Therapeutics in?
Alentis Therapeutics’s primary industry is Drug Discovery.
-
Is Alentis Therapeutics a private or public company?
Alentis Therapeutics is a Private company.
-
What is Alentis Therapeutics’s current revenue?
The current revenue for Alentis Therapeutics is .
-
How much funding has Alentis Therapeutics raised over time?
Alentis Therapeutics has raised $362M.
-
Who are Alentis Therapeutics’s investors?
Avego Management, Catalio Capital Management, Double Bioventures, Frazier Healthcare Partners, and Longitude Capital are 5 of 21 investors who have invested in Alentis Therapeutics.
-
Who are Alentis Therapeutics’s competitors?
NorthSea Therapeutics, Onward Therapeutics, Galectin Therapeutics, Sangamo Therapeutics, and Verastem are some of the 47 competitors of Alentis Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process